EGFR and neoplasm: All patients with suspected or confirmed metastatic colorectal cancer should be genotyped for tumor tissue RAS mutations, as these mutations predict resistance to the anti-epidermal growth factor receptor (EGFR) monoclonal antibodies, cetuximab and panitumumab.